Literature DB >> 9176893

Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product.

J R Polansky1, D J Fauss, P Chen, H Chen, E Lütjen-Drecoll, D Johnson, R M Kurtz, Z D Ma, E Bloom, T D Nguyen.   

Abstract

Studies of the effects of glucocorticoid (GC) and oxidative stress stimuli in differentiated cultures of human trabecular meshwork (HTM) cells have provided the rationale for our studies of a major new gene termed TIGR (trabecular meshwork inducible GC response). The TIGR clone was isolated by differential library screening using selection criteria based on the induction pattern of a new protein/glycoprotein found in HTM cultures after prolonged but not brief exposure to GCs. This GC induction pattern matched the time course and dose response required for intraocular pressure elevation in patients receiving corticosteroids. The very large, progressive induction of TIGR combined with specific structural features of its cDNA suggested that TIGR should be considered a candidate gene for outflow obstruction in glaucoma. Among the properties of TIGR cDNA were a signal sequence for secretion, several structural features for interactions with glycosaminoglycans and other glycoproteins and putative sites for cell surface interactions. In addition, the leucine zippers in the structure were related to TIGR-TIGR oligomerization that was shown to occur with native and recombinant TIGR protein. The verification that TIGR was a major stress response protein in HTM cells following hydrogen peroxide (or phorbol esters) exposure provided a potential link between GC and oxidative mechanisms thought to be involved in glaucoma pathogenesis. Pharmacological evaluation showed that basic fibroblast growth factory and transforming growth factor beta decreased the GC induction of TIGR, and certain nonsteroidal anti-inflammatory drugs protected against both GC- and oxidation-induced stress responses in HTM cells. Our recent studies of TIGR's genomic structure have shown motifs in the promoter region that suggest a basis by which multiple hormonal/environmental stimuli can regulate TIGR production and by which putative genetic alterations could lead to an overexpression of the protein. Further application of cell biology/biochemistry, molecular biology, genetic and histological approaches will be helpful in understanding the role of TIGR in different glaucoma syndromes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176893     DOI: 10.1159/000310780

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  105 in total

1.  Toward a functional annotation of the human genome using artificial transcription factors.

Authors:  Dong-ki Lee; Jin Woo Park; Youn-Jae Kim; Jiwon Kim; Yangsoon Lee; Jeonglim Kim; Jin-Soo Kim
Journal:  Genome Res       Date:  2003-12       Impact factor: 9.043

Review 2.  Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Authors:  Rebecca K Donegan; Raquel L Lieberman
Journal:  J Med Chem       Date:  2015-09-25       Impact factor: 7.446

3.  Thermally labile components of aqueous humor potently induce osteogenic potential in adipose-derived mesenchymal stem cells.

Authors:  Joshua T Morgan; Heung Sun Kwon; Joshua A Wood; Dori L Borjesson; Stanislav I Tomarev; Christopher J Murphy; Paul Russell
Journal:  Exp Eye Res       Date:  2015-02-24       Impact factor: 3.467

4.  Myocilin levels in primary open-angle glaucoma and pseudoexfoliation glaucoma human aqueous humor.

Authors:  Kyle G Howell; Anne M Vrabel; Uttio Roy Chowdhury; William Daniel Stamer; Michael P Fautsch
Journal:  J Glaucoma       Date:  2010-12       Impact factor: 2.503

Review 5.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

6.  Epitope mapping of commercial antibodies that detect myocilin.

Authors:  Athéna C Patterson-Orazem; Shannon E Hill; Michael P Fautsch; Raquel L Lieberman
Journal:  Exp Eye Res       Date:  2018-05-09       Impact factor: 3.467

7.  Targeted Disruption of the Myocilin Gene (Myoc) Suggests that Human Glaucoma-Causing Mutations Are Gain of Function.

Authors:  B S Kim; O V Savinova; M V Reedy; J Martin; Y Lun; L Gan; R S Smith; S I Tomarev; S W John; R L Johnson
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

Review 8.  Prospects for genetic intervention in primary open-angle glaucoma.

Authors:  M K Wirtz; T S Acott; J R Samples; J C Morrison
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 3.923

9.  Development of a gene therapy virus with a glucocorticoid-inducible MMP1 for the treatment of steroid glaucoma.

Authors:  Maria-Grazia Spiga; Teresa Borrás
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-01-20       Impact factor: 4.799

10.  Myocilin promotes substrate adhesion, spreading and formation of focal contacts in podocytes and mesangial cells.

Authors:  Andreas Goldwich; Michael Scholz; Ernst R Tamm
Journal:  Histochem Cell Biol       Date:  2008-10-15       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.